Posts

Showing posts with the label Biliary Atresia (BA) competitive landscape

Biliary Atresia (BA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035

Biliary Atresia (BA) Market Outlook Thelansis’s “Biliary Atresia (BA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Biliary Atresia (BA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? W...

Biliary Atresia (BA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

Biliary Atresia (BA) Market Outlook Thelansis’s “Biliary Atresia (BA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Biliary Atresia (BA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Biliary Atresia (BA) Overview Biliary atresia (BA) is a progressive, idiopathic, necroinflammatory process initially involving a segment or all of the extrahepatic biliary tree. As the disease advances, the extrahepatic bile duct lumen is obliterated, and bile flow is obstructed, resulting in cholestasis and chronic liver damage. With time, the intrahepatic biliary system becomes involved. Two different forms of BA are recognized. The more com...

Biliary Atresia (BA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Biliary atresia (BA) is a progressive, idiopathic, necroinflammatory process initially involving a segment or all of the extrahepatic biliary tree. As the disease advances, the extrahepatic bile duct lumen is obliterated, and bile flow is obstructed, resulting in cholestasis and chronic liver damage. With time, the intrahepatic biliary system becomes involved. Two different forms of BA are recognized. The more common of the two forms is the perinatal or postnatal form, which accounts for most cases. These children typically appear healthy at birth; their weights are average, and they have pigmented stools. Jaundice develops at some variable interval postnatally; typical timing is between 2 to 6 weeks of age. Because of the frequency of breast milk jaundice, the diagnosis can be missed unless a fractionated bilirubin is obtained. The less common presentation is the embryonic or fetal form, which occurs in 10% to 35% of cases. These children are cholestatic at birth; 10% to 20% h...